Cybin Inc CYBN CYBN, a clinical-stage biopharmaceutical company on the frontier of developing psychedelic-based therapies, will provide updates on its ongoing clinical trials evaluating its proprietary deuterated molecules of a psilocybin analog known as CYB003, and CYB004 DMT at its virtual R&D Day webcast on Tuesday, February 28th at 10:00 Eastern Time.
CYB003 is the first-in-human trial evaluating how these differentiated psychedelic-based therapeutics can be used for the treatment of depression and anxiety disorders, which affect millions of people worldwide.
Register for the event here:
https://lifescievents.com/event/cybin-rd-day/
Learn more:
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Featured photo by Louis Reed on Unsplash
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
